New drug combo trial offers hope for advanced breast cancer patients
NCT ID NCT07285382
Summary
This study is testing two different doses of a drug called dalpicicl when combined with letrozole for people with advanced HR-positive, HER2-negative breast cancer. The trial will enroll 120 participants who haven't received prior treatment for their advanced cancer to see which dose works better at controlling the disease. Researchers will measure how long patients live without their cancer getting worse and monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Qingdao University Affiliated Hospital
RECRUITINGQingdao, Shandong, 266000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Affiliated Hospital of Dalian Medical University
RECRUITINGDalian, Liaoning, 116027, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.